ISG Technologies changes name to CedaraPACS and image-guided surgery firm ISG Technologies has changed its name. Now called Cedara Software, the Mississauga, ON-based firm has embarked on a worldwide corporate branding campaign intended to
PACS and image-guided surgery firm ISG Technologies has changed its name. Now called Cedara Software, the Mississauga, ON-based firm has embarked on a worldwide corporate branding campaign intended to highlight the companys healthcare software products and services. The name change and the companys new stock trading symbols are contingent on shareholder approval. Until they receive approval, the firm will continue to trade under ISO (Toronto Stock Exchange) and ISGTF (Nasdaq).
Cedara will be divided into three core businesses: software and service, image management, and image-guided therapy. Two of the three businesses have gained new executive leadership in the past year. The company named Arun Menawat to the post of general manager/president of the software and service division, which develops the companys Image Application Platform software, designed for 3-D post-processing, CT, digital x-ray, MRI, mammography, nuclear medicine, and ultrasound equipment. Cedara has also appointed Alyn Ford to the position of general manager/vice president of its image management business, which develops software products that display, analyze, and store medical images (PNN 6/99).
Can Portable Dual-Energy X-Ray be a Viable Alternative to CT in the ICU?
September 13th 2024The use of a portable dual-energy X-ray detector in the ICU at one community hospital reportedly facilitated a 37.5 percent decrease in chest CT exams in comparison to the previous three months, according to research presented at the American Society of Emergency Radiology (ASER) meeting in Washington, D.C.
New Meta-Analysis Examines MRI Assessment for Treatment of Esophageal Cancer
September 12th 2024Diffusion-weighted MRI provided pooled sensitivity and specificity rates of 82 percent and 81 percent respectively for gauging patient response to concurrent chemoradiotherapy for esophageal cancer, according to new meta-analysis.
Study for Emerging PET/CT Agent Reveals ‘New Standard’ for Detecting Clear Cell Renal Cell Carcinoma
September 11th 2024Results from a multicenter phase 3 trial showed that the PET/CT imaging agent (89Zr)Zr-girentuximab had an 85.5 percent mean sensitivity rate for the diagnosis of clear cell renal cell carcinoma.
Can Radiomics and Autoencoders Enhance Real-Time Ultrasound Detection of Breast Cancer?
September 10th 2024Developed with breast ultrasound data from nearly 1,200 women, a model with mixed radiomic and autoencoder features had a 90 percent AUC for diagnosing breast cancer, according to new research.